Ayala Pharmaceuticals
Targeted Therapies for People with Rare Cancers
Company Overview
Snapshot
Founded in January 2017, Ayala Pharmaceuticals operates with 11–50 employees. The company has raised a total of $102 million across 5 funding rounds from 6 investors. A significant milestone occurred in January 2023 when Ayala Pharmaceuticals completed its merger with Advaxis.
Business overview
Ayala Pharmaceuticals is a clinical-stage precision oncology company focused on developing and commercializing small molecule therapeutics for rare and aggressive cancers, particularly in genetically defined patient populations. Its core product candidates, AL101 and AL102, target cancer by addressing underlying drivers of tumor growth through the aberrant activation of the Notch pathway with gamma-secretase inhibitors (GSIs). The company serves the pharmaceutical and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.
Strategic signal
In May 2024, Ayala Pharmaceuticals filed Form 15 to voluntarily deregister and suspend its reporting obligations. This action signals a strategic shift away from public market scrutiny, likely following its acquisition and subsequent merger activities, indicating a move towards a more private operational phase for the company.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent significant corporate action involving Ayala Pharmaceuticals?
- In May 2024, Ayala Pharmaceuticals filed Form 15 to voluntarily deregister and suspend its reporting obligations, indicating a move away from public market reporting.
- When did Ayala Pharmaceuticals complete its merger with Advaxis?
- Ayala Pharmaceuticals completed its merger with Advaxis on January 19, 2023, as announced by Advaxis and Ayala Pharmaceuticals.
- Did Ayala Pharmaceuticals undergo a reverse merger recently?
- In October 2023, Ayala Pharmaceuticals completed a reverse merger with Biosight.
- When did Ayala Pharmaceuticals conduct its Initial Public Offering?
- Ayala Pharmaceuticals conducted its Initial Public Offering in May 2020, listing on NASDAQ.
- Which investors participated in Ayala Pharmaceuticals' May 2019 funding round?
- In May 2019, Ayala Pharmaceuticals received funding from Novartis and Shavit Capital Fund.